All News
The RheumNow Week in Review – 21 July 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com:
Read ArticleGouts' Increasing Hospitalizations and Poor Management
Numerous studies have shown that gout hospitalizations have increased in the last decade. Also worrisome is a new studiy showing that patients admitted to the hospital are less likely to have received recommended urate-lowering treatment (ULT).
Read ArticleEULAR 2017 – Day 2 Highlights
The heat was on at EULAR 2017 for busy presenters and attendees navigating the 104F degree temperatures at the indoor/outdoor IFEMA Convention center in Madrid.
Day 2 (Thursday) were big days for gout, drug safety, psoriatic arthritis and spondyloarthritis.
Read ArticleNew insights into the impact of pegloticase in chronic refractory gout
Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions. It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions.
Read ArticleMixed Results with Combination Therapy in Gout
Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.
Read ArticleThe RheumNow Week in Review – 2 June 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com.
Read ArticleNew BSR 2017 Gout Guidelines
The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.
Read ArticleMortality in Gout Increased
Two current articles in the Journal of Rheumatology address issues surrounding mortality risk among those with new and established gout.
Read ArticleThe RheumNow Week in Review – 17 March 2017
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Read ArticleThe UnderManagement of Gout
Most physicians believe they understand and can manage gout. Yet, the number of gout patients has risen at an alarming rate and the introduction of 4 new drugs has done little to close the education gap and improve the care and outcomes of gout patients. Misuse, misunderstandings and missed opportunities abound in the wide world of gout.
Read ArticleEULAR Treat-to-Target Guidelines for Gout
Treat-to-target (T2T) works when they are pragmatic and conform well to daily practice.
Gout is an ideal therapeutic area where T2T could be and should be applied.
Read ArticleThe RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read ArticleThe RheumNow Week in Review – 10 February 2017
Dr. Jack Cush discusses the news and reports from this week on RheumNow:
Read ArticleThe RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read ArticleGout is Undermanaged
Gout should be one of the easiest and best managed of rheumatic disorders. However, numerous deficits exist with regard to the treatment and long-term care of gout.
Read ArticleIncreased Cardiovascular Risk with Gout
Most patients who present with gout to rheumatology clinics are at very high risk of cardiovascular (CV) disease, Spanish researchers found.
Read ArticleStatins Don't Increase Risk of Colchicine Myopathy
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
Read ArticleThe RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read ArticleRheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read ArticleBariatric Surgery Thwarts Gout and Hyperuricemia
The rising incidence of gout has been directly linked to the obesity epidemic. The influence of obesity on gout was further tested in a cohort study of obese patients undergoing bariatric surgery as part of the Swedish Obese Subjects (SOS) study.
Read Article